ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage immunotherapy company that develops next-generation therapies to treat cancer and infectious diseases. Its immunotherapy platform activates the …
Bullish Sentiments for ImmunityBio (IBRX) After Trial Success and FDA Authorization
view original post